CureVac NV Asset Resilience Ratio

Latest as of September 2025: 0.27%

CureVac NV asset resilience ratio. CureVac NV (5CV) has an Asset Resilience Ratio of 0.27% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of CureVac NV to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€3.12 Million

≈ $3.65 Million USD Cash + Short-term Investments

Total Assets

€1.14 Billion

≈ $1.33 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of CureVac NV (2018–2024)

Asset resilience ratio of CureVac NV from 2018 to 2024. This chart shows how CureVac NV's Asset Resilience Ratio has changed over time. Read CureVac NV (5CV) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down CureVac NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 5CV asset base.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€3.12 Million	0.27%
Total Liquid Assets	€3.12 Million	0.27%

Asset Resilience Insights

Limited Liquidity: CureVac NV maintains only 0.27% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

CureVac NV Industry Peers by Asset Resilience Ratio

Compare CureVac NV's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	Biotechnology	35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd SHE:300294	Biotechnology	23.15%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Achieve Life Sciences Inc F:SP4P	Biotechnology	3.60%

CureVac NV Asset Resilience Ratio by Year (2018–2024)

CureVac NV asset resilience ratio by year from 2018 to 2024. The table below shows the annual Asset Resilience Ratio data for CureVac NV.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.45%	€3.62 Million ≈ $4.23 Million	€802.83 Million ≈ $938.59 Million	+0.11pp
2023-12-31	0.34%	€2.66 Million ≈ $3.11 Million	€788.25 Million ≈ $921.55 Million	-0.18pp
2022-12-31	0.52%	€4.49 Million ≈ $5.25 Million	€860.47 Million ≈ $1.01 Billion	+0.12pp
2021-12-31	0.40%	€4.65 Million ≈ $5.43 Million	€1.16 Billion ≈ $1.35 Billion	+0.23pp
2020-12-31	0.17%	€2.62 Million ≈ $3.06 Million	€1.51 Billion ≈ $1.77 Billion	-0.94pp
2019-12-31	1.12%	€1.46 Million ≈ $1.70 Million	€130.62 Million ≈ $152.71 Million	-30.12pp
2018-12-31	31.24%	€39.25 Million ≈ $45.89 Million	€125.66 Million ≈ $146.91 Million	--

pp = percentage points

About CureVac NV

F:5CV Germany Biotechnology

Market Cap

$1.03 Billion

€879.52 Million EUR

Market Cap Rank

#9102 Global

#1166 in Germany

Share Price

€3.91

Change (1 day)

-0.61%

52-Week Range

€3.42 - €4.70

All Time High

€108.20